{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-029510","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.402381+00:00","generated_at":"2026-05-25T23:37:14.069644+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M","bullets":["Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.","GAAP net loss of $42.7M ($1.41 per share) for FY 2024; non-GAAP income $15.0M ($0.49 per share).","Q4 2024 total revenue $76.2M; core revenue up 14% to $76.0M; GAAP loss $5.9M, non-GAAP income $1.2M.","Ended 2024 with $828.6M cash & investments ($26.87/share); cash from ops $21.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-029510","json":"https://secwatch.observer/filing/0000950170-25-029510.json","markdown":"https://secwatch.observer/filing/0000950170-25-029510.md","text":"https://secwatch.observer/filing/0000950170-25-029510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000095017025029510/0000950170-25-029510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000095017025029510/flgt-20250228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:37:14.069644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}